Boehringer files Humira biosimilar in EU, US – PharmaTimes

Boehringer Ingeheim’s biosimilar to AbbVie’s mega blockbuster Humira has been accepted for review on both sides of the Atlantic, after having shown comparability in late-stage trials.Humira (adalimumab), an anti-TNF monoclonal antibody, pulls in annual sales of nearly $15 billion across its range of indications for inflammatory diseases.It is currently approved in the US, EU and other markets for multiple indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

Read The Full Source: Boehringer files Humira biosimilar in EU, US – PharmaTimes

Tags:
0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2017 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Translate »

Log in with your credentials

Forgot your details?